^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

Excerpt:
The five substitutions that conferred a high degree of resistance to AC220 in vitro were cross-resistant to sorafenib in cell-based growth and biochemical assays (Supplementary Fig. 4). The degree of relative resistance to sorafenib associated with these mutants was generally similar to that observed with AC220.
DOI:
https://dx.doi.org/10.1038%2Fnature11016
Trial ID:
Evidence Level:
Resistant: D – Preclinical
New
Title:

Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies

Excerpt:
AC220 demonstrated a similar pattern of resistance as observed with sorafenib treatment (Fig. 2A).
DOI:
https://dx.doi.org/10.1158%2F1078-0432.CCR-13-2052